Core-005

核心005

• 批准号: 10409669
• 负责人: JAMES E. HEUBI
• 金额: $ 60.76万
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-14 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10409669
• 关键词: Center for Translational Science Activities; Clinical; Clinical Research; Clinical Sciences; Communities; Data; Development; Disease; Environment; Future; Goals; Health Personnel; Infrastructure; Knowledge; Monitor; Organoids; Participant; Process; Protocols documentation; Recording of previous events; Research; Research Design; Research Personnel; Resources; Special Population; Surveys; Training; Translational Research; Underrepresented Populations; Underserved Population; clinical center; empowered; experience; first-in-human; gene therapy; health disparity; innovation; multidisciplinary; process optimization; programs; recruit; research study; skills training; tool; translational research program

The goal of the Hub Research Capacity Core of the Center for Clinical and Translational Science and Training (CCTST) is to support the clinical and translational research enterprise of the future. As outlined in the FOA, the Hub includes two cores: Participant and Clinical Interactions (PCI) and Integrating Special Populations (ISP). The PCI Core will focus on improvement of infrastructure and processes to conduct clinical and translational research, with an overall goal to enhance the experience of participants and investigators. This will be accomplished through the following Specific Aims: 1) engage stakeholders in conducting clinical and translational research; 2) promote development of a diverse, multidisciplinary workforce of the future; and 3) optimize the processes to conduct high-quality research studies in a safe environment. Examples of the approaches to accomplish these aims include: engaging stakeholders through conducting biannual surveys; extending clinical and translational research capabilities to underserved populations and those with health disparities through a mobile unit; developing skills training in clinical research to provide knowledge on clinical research implementation and the resources available to study investigators and study teams; streamlining protocol assessment, review, approval, and monitoring; and utilizing state-of-art Clinical and Translational Research Center (CTRC) infrastructure and highly qualified research personnel to conduct first-in-man treatments such as gene therapy or use of organoids for treatment of diseases. The CCTST has a strong history of effectively integrating special populations into clinical and translational research. Our Integrating Special Populations Initiative (ISPI) will build on well-developed programs by increasing the participation of special populations in research design and equipping research teams with the tools needed to overcome barriers to research participation for special populations. To achieve this goal, we will 1) support innovative strategies for engaging underrepresented populations in research studies; 2) expand infrastructure support for integrating special populations into research; and 3) optimize recruitment of special populations using biomedical data. These efforts will result in the development of a network of health care providers, community partners, and researchers empowered to launch new research that will impact the most vulnerable and hardest to reach special populations experiencing the greatest burden of health disparities.

临床和转化科学中心枢纽研究能力核心的目标 培训（CCTST）是为了支持未来的临床和转化研究企业。如在 FOA，枢纽包括两个核心：参与者和临床相互作用（PCI）和集成特殊 种群（ISP）。 PCI核心将着重于改进基础架构和过程以进行临床 和转化研究，总体目标是增强参与者和研究人员的经验。 这将通过以下特定目的完成：1）让利益相关者进行临床 和翻译研究； 2）促进发展未来多样化的跨学科劳动力；和 3）优化在安全环境中进行高质量研究的过程。示例 实现这些目标的方法包括：通过进行双年度调查与利益相关者参与； 将临床和转化研究能力扩展到服务不足的人群和健康的人群 通过移动单元的差异；在临床研究中开发技能培训，以提供有关临床知识 研究实施以及可用于研究研究人员和研究团队的资源；精简 协议评估，审查，批准和监视；并利用最先进的临床和翻译 研究中心（CTRC）基础设施和高素质的研究人员进行第一名 诸如基因疗法或使用器官治疗疾病的治疗方法。 CCTST有强大 有效地将特殊人群纳入临床和转化研究的历史。我们的整合 特殊人口倡议（ISPI）将通过增加的参与来建立在发达的计划的基础上 研究设计中的特殊人群并为研究团队配备了克服所需的工具 特殊人群研究参与的障碍。为了实现这一目标，我们将1）支持创新 使代表性不足的人群参与研究的策略； 2）扩大基础设施支持 将特殊人群纳入研究； 3）使用 生物医学数据。这些努力将导致建立卫生保健提供者网络，社区 合作伙伴和研究人员有权发起新的研究，这将影响最脆弱和最困难的研究 接触特殊人群，承受着最大的健康差异负担。